Head-to-head evidence
Quetiapine (Seroquel XR) vs Risperidone (Uzedy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Quetiapine (Seroquel XR)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00640601 · Phase 3 · completed
This was a nonrandomized, single-group, open-label study of 295 treated participants, without a placebo or active comparator. Although 56.88% were reported to have improved clinical benefit on the primary CGI-CB measure, the uncontrolled design cannot determine how much of the improvement was due to quetiapine rather than other factors.
Next expected readout: February 2032 · NCT07152184 (registry estimate)
Risperidone (Uzedy)
Marketed by Teva Pharmaceutical Industries
NCT03503318 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 544 participants assigned to placebo, monthly TV-46000, or every-two-month TV-46000. The hard clinical primary endpoint was time to impending relapse, and it was statistically significantly favorable for both monthly treatment (13/183 vs 53/181; p<0.0001) and every-two-month treatment (23/179 vs 53/181; p<0.0001).
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Quetiapine (Seroquel XR)'s landscape · Risperidone (Uzedy)'s landscape